Search
Close this search box.

Industry News, Trustworthy Insights

Sign in
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Popular Companies:
Private Equity

Carlyle Confirms Major Focus on Biotech | Exclusive

Carlyle Group and its life-sciences arm, Abingworth, are strengthening their investment in Australian biotech company Opthea, in pursuit of bringing the company’s lead therapeutic candidate, OPT-302, to market. OPT-302 targets wet macular degeneration, an eye disorder that can cause vision loss.

From left, William Conway, Daniel D’Aniello and David Rubenstein founded the Carlyle Group. Photo: Shutterstock
From left, William Conway, Daniel D’Aniello and David Rubenstein founded the Carlyle Group. Photo: Shutterstock  

More from Krugman Insights

Industry news used by professionals

Try £4.99 per month

Subscribe
Already a member?
Weekly Digest

All the week’s industry events straight to your inbox.

Before your sign up, please read terms of use and privacy policy.

Trending

FREE Weekly Newsletter

Trusted industry insights used by Professionals

By signing up you agree to our terms of use and privacy policy.

More from Krugman Insights

7 Bell Yard, London, England, WC2A 2JR

Other

About

Legal & Privacy

© Copyrights 2024 - All Rights Reserved To Krugman Insights

Join us on
Linked
Linkedin-in
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Sign in

Password Reset

You will soon receive a Reset Password link

FREE Weekly Newsletter

Trusted industry insights used by Professionals

By signing up you agree to terms of use and privacy policy.
Profile
Subscribe
© 2024 Krugman Insights. All rights reserved.

Send us your article

[formidable id=3]